» 2009

Animal Health News & Notes for April 3, 2009 4/3/2009

printer friendly version

Brakke Consulting's
Animal Health News & Notes for April 3, 2009

Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon, DVM, MBA
earnings news
other news
Brakke Consulting
PharmaCom BioVet
MAY 12-13, 2009
The Animal Agriculture Alliance's Eighth Annual Stakeholders Summit will be held May 12-13, 2009 in Alexandria, Virginia.  This year's topic is Politics, Activism and Religion: Influencing the Debate on Animal Welfare in America.
For more information please go to www.animalagalliance.org
> The Provimi Group announced results for 2008.  Revenues were EUR 2.1 billion ($3.0 billion), an increase of 12% compared to 2007.  The increase was mainly a result of higher raw material costs, as well as a positive pricing and mix effect.  On a like-for-like basis, sales growth was 15%. Profit from operations was EUR 92 million ($130 million). (company press release)  
> Brakke Consulting announced the opening of a new office in the Kansas City area. The new Brakke Consulting office will be staffed on a rotating basis by three current Brakke personnel: Ron Brakke, president; John Mannhaupt, vice president; and Joel Adamson, consultant. Contact information for the Kansas City office will be forthcoming.  (company press release)
> Provimi announced it has acquired the 100% ownership of Vetcare, an Indian manufacturer and exporter of animal health and nutrition products for food and companion animals. The Provimi group set up a joint venture with Vetcare in 1999. Financial details were not disclosed. (Animal Pharm)
> Generex Biotechnology Corporation announced plans to pursue the regulatory approval for Generex Oral-lyn for therapeutic use in cats and dogs with diabetes mellitus. The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the company's proprietary RapidMist device. (Fox Business)
> Envirologix launched a rapid test for melamine contamination of the raw materials used in animal feed and pet food. The QuickTox kit is an on-site immunoassay that delivers results in five minutes, and is capable of detecting melamine contamination at 2.5 parts per million, the maximum limit for animal feeds established by regulatory agencies worldwide. (Animal Pharm)
> PharmaCom BioVet, Inc. announced the execution of a joint venture agreement with an unnamed research development company to finalize the development of a compound with the potential to become a viable treatment of specific cancers for companion animals. The compound is in the family of Histone Deacetylase (HDAC) inhibitors. Terms were not disclosed. (TradingMarkets.com)  
> NEW ZEALAND   Novartis Animal Health announced the New Zealand launch of Zolvix (monepantel), the revolutionary, new sheep drench which kills gastrointestinal worms, even those resistant to existing drenches. Zolvix is the first product of a new class of resistance-breaking anthelmintics called the Amino-Acetonitrile Derivatives (AADs) and has a unique mode of action. (company press release) 
> CZECH REPUBLIC - BSE   The Czech state veterinary service reported discovery of a new case of BSE in a 66-month-old cow in the north of the country, and announced it would cull around 200 related cattle. The Czechs last reported two cases of BSE in cows in 2007. (Reuters)
It’s been another interesting week for in animal health.  I was able to attend the better part of the Invest Midwest Venture Capital Forum in KC during the week.  This meeting was well attended by venture capital firms but only one animal health company was on the program.  It’s very apparent that animal health has a story to be told, but its not being presented properly, or what is being presented is not being heard.  We hope to assist in remedying this situation in the near future.  Please stay tuned for more information on a new initiative to bring startup animal health companies and venture capital together. 
Another observation we have is that the industry is currently stalled out in new business development activities.  The current expectations and rumors related to what products or product lines might become available out of the pending Pfizer/Wyeth and Merck/Schering mergers seems to be a reason for not moving forward on other opportunities.  Analysis paralysis based on speculation could be embarrassing and non-productive if companies are not careful.
Earlier this week we announced that we will open an office in Kansas City this month.  We’re pleased to be a part of the KC Animal Health Corridor and look forward to working even more closely with the many companies in the area.  We’ll be providing the Brakke KC office contact information in a few days.
Have a great weekend!!
Ron Brakke
This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by
and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting's services and syndicated studies, visit our website at  www.brakkeconsulting.com.
Brakke Consulting, Inc.
2735 Villa Creek, Suite 140
Dallas, TX  75234    USA